Weekly Digest – Feb 2024 Weekly Digest – Feb 2024 21 Feb 2024: Mabwell receives IND Approval from FDA for Novel B7-H3 ADC 7MW3711 The IND application is for advanced malignant solid tumors, and the clinical trial for 7MW3711 has […]
Weekly Digest – Feb 2024 Weekly Digest – Feb 2024 20 Feb 2024: Daiichi Sankyo plans €1B expansion to enhance Antibody-Drug Conjugate production in Germany Daiichi Sankyo unveils a €1 billion expansion plan to bolster antibody-drug conjugate (ADC) production in […]
Weekly Digest – Feb 2024 Weekly Digest – Feb 2024 19 Feb 2024: Gilead signs antibody agreement with Biocytogen amid growing ADC excitement Biocytogen Pharmaceuticals announces a new antibody evaluation and option agreement with Gilead Sciences, providing access to its […]
Weekly Digest – Feb 2024 Weekly Digest – Feb 2024 19 Feb 2024: Datopotamab deruxtecan’s BLA accepted in the US for advanced NSCLC in previously treated patients Datopotamab Deruxtecan is a TROP2-directed DXd antibody-drug conjugate (ADC) being jointly developed by […]
